ABSTRACT
@#肺癌是目前全世界发病率及病死率均居前列的恶性肿瘤。近年来，基于驱动基因的分子靶向精准治疗彻底改变了晚 期肺癌患者的治疗模式，新型抗肿瘤药物层出不穷。安罗替尼（AL3818，anlotinib）是中国自主研发的一种新型小分子多靶点酪 氨酸激酶抑制剂（tyrosine kinase inhibition，TKI），其具有抗肿瘤血管生成和抑制肿瘤细胞生长的作用，且安全性较好，目前已被 国家食品药品监督管理局（China Food and DrugAdministration，cFDA）批准用于肺癌的三线及以上治疗。本文就安罗替尼抗肿 瘤作用机制、相关临床研究、寻找预测疗效的标志物及不良反应等方面在肺癌中的研究进展作一综述。
ABSTRACT
<p><b>OBJECTIVE</b>To explore the reasonable therapeutic strategy for different types of epicanthus.</p><p><b>METHODS</b>Patients with epicanthus were classificated according to the shape, extent and inner canthal distance and treated with different methods appropriately. Modified asymmetric Z plasty with two curve method was used in lower eyelid type epicanthus, inner canthus type epicanthus and severe upper eyelid type epicanthus. Moderate upper epicanthus underwent '-' shape method. Mild Upper epicanthus in two conditions which underwent nasal augumentation and double eyelid formation with normal inner canthal distance need no correction surgery. The other mild epicanthus underwent '-' shape method.</p><p><b>RESULTS</b>A total of 66 cases underwent the classification and the appropriate treatment. All wounds healed well. During 3 to 12 months follow-up period, all epicanthus were corrected completely with natural contour and unconspicuous scars. All patients were satisfied with the results.</p><p><b>CONCLUSIONS</b>Classification of epicanthus hosed on the shape, extent and inner canthal distance and correction with appropriate methods is a reasonable therapeutic strategy.</p>